Psilocybin for Depression in Veterans
Bottom line: A VA trial may suggest psilocybin, combined with therapy, was associated with potential benefits for depression in veterans, addressing gaps in prior research.
James is a veteran. He’s been staring at the ceiling in a VA hospital for weeks, stuck in a loop of grief and guilt. He’s not alone — nearly one in five veterans suffer from major depression, and antidepressants often don’t help. But in a VA lab, researchers are testing a radical idea: what if a single dose of psilocybin, the compound in magic mushrooms, could break that cycle? The trial isn’t open yet, but the questions it raises are already unsettling the foundations of mental health treatment. Why is the VA, an institution known for its rigid protocols, running a trial on a substance once called a “drug of abuse”? And if psilocybin works, what does that mean for veterans like James — people who’ve spent decades fighting for their country and now need help fighting for their minds?

The Veteran’s Dilemma
Depression in veterans is more than a number — it’s a crisis. The VA reports over 300,000 veterans are diagnosed with major depressive disorder each year, and many have treatment-resistant depression. Traditional antidepressants work for some, but they take weeks to take effect and come with side effects like weight gain, sexual dysfunction, and emotional numbness. For veterans, who have already faced trauma, these side effects can feel like another burden.
Enter psilocybin. This compound, found in certain mushrooms, is drawing interest for its potential to rapidly reduce depression symptoms. Unlike antidepressants, which adjust neurotransmitter levels, psilocybin seems to work differently — it alters brain networks and promotes neural plasticity. The VA study is testing this, combining a single dose of psilocybin with a brief course of Acceptance and Commitment Therapy (ACT), a therapy that helps patients build psychological flexibility.
But the trial is not only about psilocybin. It also includes a control group receiving modafinil, a stimulant, and zolpidem, a sedative, to address the challenge of managing placebo effects. The inclusion of pimavanserin, an antipsychotic, suggests researchers are aware of the intense emotional experiences psilocybin can trigger. This is a deliberate attempt to isolate psilocybin’s true effects from the power of expectation — a key problem in earlier studies.
The VA’s involvement is a shift. For decades, it has been cautious about psychedelic research, citing safety and regulation concerns. Now, the VA Office of Research and Development is leading a trial that could change how mental health care is handled — not just for veterans, but for the general population.
The Science Behind the Spark
Psilocybin’s antidepressant effects go beyond the “trip.” The compound is converted into psilocin, which acts on serotonin receptors, especially the 5-HT2A receptor. This interaction seems to spark a chain of events that alter brain connectivity, promoting new synapses and better communication between brain regions. A related study from Europe PMC suggests these changes may occur at multiple levels — from molecules to neural circuits to clinical outcomes.
One interesting finding from the systematic review is that psilocybin may improve depression through multiple mechanisms. It appears to boost neuroplasticity, reduce inflammation, and modulate the default mode network (DMN), a brain network linked to self-referential thinking and rumination. This modulation might help people break free from the negative thought patterns that fuel depression.
The VA trial is especially focused on psychological flexibility — a key concept in ACT. Psychological flexibility means being present, open to experience, and adapting to change. In depression, this means tolerating difficult emotions without being overwhelmed. The study’s design reflects this — participants will attend ACT sessions before and after the psilocybin dose, helping them integrate the experience and reinforce the therapy.
But the science is still early. Psilocybin has shown promise in trials, but the long-term effects, potential for dependency, and optimal dosing are still unclear. The VA study is among the first to target veterans, a group with unique mental health challenges. This focus is practical — but it’s also ethical. Veterans have been overlooked in psychedelic research despite high rates of PTSD, depression, and substance use disorders.
A New Model for Mental Health Care
The VA trial is part of a broader shift in mental health care. Traditional models often focus on symptom management, using medications that may only provide temporary relief. Psilocybin, by contrast, offers a different approach — one that emphasizes transformation and healing. The study’s focus on psychological flexibility and neural plasticity aligns with research suggesting mental health is not just about managing symptoms, but about rewiring the brain.
This shift is also showing up in U.S. legislation. The New Mexico Medical Psilocybin Act, which took effect in April 2025, is a landmark example of how policy is catching up with science. The law sets up a regulated system for supervised psilocybin use, including licensing for producers and clinicians, with full implementation expected by the end of 2026. This model, which prioritizes safety, equity, and research, could be a template for other states and countries.
The VA study is part of this movement. It’s not just about finding a new treatment for depression — it’s about rethinking the entire approach to mental health care. If psilocybin proves effective, it could lead to a shift where psychedelic-assisted therapies become standard for a range of mental health conditions.
Frequently Asked Questions
Q: Is psilocybin safe for veterans with mental health conditions?
A: Safety is a top priority in the VA trial. The study includes interventions like pimavanserin to manage potential side effects. But psilocybin still carries risks, and its long-term safety profile is under study. The VA is monitoring participants closely.
Q: Will the trial be accessible to all veterans?
A: The study is designed to reflect the demographics and medical complexity of the VHA patient population. However, access will depend on eligibility criteria, which will be determined as the study progresses. The VA is committed to inclusivity.
Q: How long will the trial take?
A: The trial is expected to take several years. Researchers are working to gather comprehensive data on the safety and efficacy of psilocybin for depression in veterans. The timeline will depend on recruitment and study design.
Q: What happens if the trial is successful?
A: If psilocybin proves effective, it could lead to new treatment protocols. But even with positive results, approval and widespread use will require further research and regulatory processes.
Q: Can psilocybin be used outside of a clinical setting?
A: Psilocybin is still a Schedule I substance in the U.S., so it’s not legal for recreational or therapeutic use outside of approved trials. But legislation like the New Mexico Medical Psilocybin Act is setting the stage for future changes.
Sources
- ¶Psilocybin for Depression in Veterans
- ¶Multilevel Mechanisms and Clinical Efficacy of Psilocybin in Depression Treatment: A Systematic Review
- ¶Ibogaine for Substance Use Disorders
- ¶The New Mexico Medical Psilocybin Act and current trends in the United States psychedelic policy
Educational Disclaimer
This article is for informational and educational purposes only. It is not medical advice, mental health advice, diagnosis, treatment guidance, or a recommendation to use any substance, supplement, therapy, or protocol.
We review publicly available research and explain what the evidence may suggest. Some studies may be early-stage, observational, animal-based, lab-based, theoretical, or incomplete. Always consult a qualified professional before making health-related decisions.
If you or someone you know is struggling, you are not alone. In the US, call or text 988 (Suicide & Crisis Lifeline). Elsewhere, contact your local emergency or crisis service.
Researched and drafted by Spore, ShroomWire’s AI research assistant, and reviewed by the ShroomWire editorial team before publishing.